Wednesday, September 26, 2007

HealthSonix HSXI Announces Joint Venture with Abbot Labs / Exclusive interview with CEO Michael Ivezic

(ABT)(MRK)(HSXI)(SNY)(JNJ)

HealthSonix and Abbott Laboratories Launch Innovative Combination Therapy Program for Patients With Advanced Rheumatoid Arthritis
Wednesday September 26, 11:08 am ET

Significant Development in the Fight Against Advanced Rheumatoid Arthritis

IRVINE, CA--(MARKET WIRE)--Sep 26, 2007 -- HealthSonix, Inc. HSXI announced today that the joint marketing program with Abbott Laboratories ABT has commenced in Southern Ontario, Canada. The program is the first of its kind and offers Rheumatologists the option of prescribing "combination therapy" for patients with advanced rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

"The guidelines published by the American College of Rheumatology [ACR] for rheumatoid arthritis state that 'the ultimate goals in managing RA are to prevent or control joint damage, prevent loss of function, and decrease pain,'" said Dieter D. Doederlein, Vice President Corporate Development of HealthSonix. "To maintain joint function, the guidelines suggest that 'regular participation in dynamic and even aerobic conditioning exercise programs improves joint mobility, muscle strength, aerobic fitness and function, and psychological well being without increasing fatigue or joint symptoms.' That is why the combination therapy now offered by Abbott Laboratories and HealthSonix is a significant new development for both rheumatologists and their patients," said Doederlein.

Abbott's biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.

The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in Range Of Motion; reduction in joint and muscle stiffness; improvement in the willingness to move; improvement in functional strength and functional mobility; improvement in social and psychological factors.

"This new program represents a significant development in the fight against arthritis because the ACR guidelines stress that the combination of medications and non-pharmacological therapies is the optimal way to treat the patients," said Doederlein.

HealthSonix, Inc. HSXI is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: http://www.healthsonix.com/ or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact: Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact

Editors Note:
In a recent press release and interview, CEO Michael Ivezic stated that HealthSonix was preparing for a move to a senior exchange by the end of 2007. At that time we offered the opinion that in order to meet the minimum stock price of the AMEX which is $2.00/share, the company would need to announce a major development. It is our opinion that today's news could well be that event. HealthSonix has flown below Wall Street's radar until today. Once institutions and retail investors who hold Abbot Labs ABT stock become aware of this partnership, it may be seen as an opportunity to strengthen the Health Care sector of their portfolios for pennies on the dollar. We will continue to monitor this situation closely.

HealthSonix is a member of the "CT Triple Crown"
CT does not accept cash, stock, warrants, or the promise thereof,
to profile or promote any company.
He works for YOU, the Christian Investor.

No comments:

Post a Comment

Your comment will be posted within 1 hour of acceptance by our editorial staff.